This article was originally posted on The Limbic Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing...Continue Reading
UPCOMING PATIENT MEETING You’re invited to join us at our next Wellington Patient Meeting Thursday 1st July 2021, 5pm BNZ Partners Centre, Level 10, Ricoh House1 Victoria StreetWellington 6011 Patients and their supporters are welcome to join the trustees for light refreshments and a brief presentation related to issues affecting patients and carers living with...Continue Reading
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new...Continue Reading
This Policy Review presents the International Myeloma Working Group’s clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients ...Continue Reading
This article was originally posted on Cure Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies. Cristina Gasparetto, MD: We talked about your quality of life. Sometimes patients, they listen to us as physicians, but they listen to patients more. What type of...Continue Reading
Australian patients with amyloidosis face a lottery where they may be denied effective medication depending on how strictly their physician interprets the letter of PBS rules, a haematologist has told a parliamentary inquiry. Dr Peter Mollee, head of the Myeloma Service and the Princess Alexandra Hospital Amyloidosis Centre in Brisbane, told the House of Representatives...Continue Reading
This article was originally published on NZ Herald.co.nz Do you know why you’re here? I thought I did until I was asked. I’m in a small, windowless brick room at Auckland Hospital. This starter for 10 was delivered by a man who was to become my clinical haematologist. Until that morning I had no idea...Continue Reading
This article was originally published on The Limbic Australian blood cancer patients are being denied access to life-extending drugs and treatments because of long delays and excessive regulation by the Pharmaceutical Benefits Advisory Committee (PBAC), a parliamentary inquiry has been told. Leading haematologist Professor Andrew Spencer said the registry of myeloma cases established some eight...Continue Reading
This article was originally published by Medical News Today Multiple myeloma is a type of blood cancer that affects plasma cells. Doctors use a three-step staging system to classify the severity of multiple myeloma and whether it has spread. A person may experience different types of symptoms in each stage, and survival rates will change...Continue Reading
This article was originally posted by Journal of Experimental Pharmacology Offidani et al. Journal of Experimental Pharmacology 2021:13 245–264 Offidani, Corvatta, Morè & Olivieri Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging...Continue Reading
